GEN Exclusives

More »

GEN News Highlights

More »
Nov 2, 2009

Amylin to Receive $75M in Obesity Alliance with Takeda

  • Amylin Pharmaceuticals and Takeda Pharmaceutical are joining forces to develop and commercialize therapies for obesity and related indications. Takeda will pay Amylin $75 million up front for a license to its Phase II program with pramlintide/metreleptin and davalintide.

    Amylin stands to earn $1 billion in development, commercialization, and sales-based milestones. The agreement also includes additional compounds from both companies' obesity research programs.

    Amylin is responsible for developing each potential molecule through Phase II in the U.S. Takeda will lead development beyond Phase II in the U.S. and all development activities outside the U.S. In most instances, Amylin will be responsible for 20% of development costs associated with obtaining approval for products in the U.S. Takeda will be responsible for 100% of development costs associated with obtaining approval for products outside the U.S.

    Takeda will lead product commercialization, both in the U.S. and outside the U.S., and will be responsible for 100% of commercialization costs. Amylin will receive tiered, double-digit royalty payments based on global product sales. Amylin also has the option to co-commercialize the first two approved products in the U.S. and any follow-on products containing the identical active ingredients.


Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »